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Purpose: Despite advances in multimodality management of brain metastases, local pro-
gression following stereotactic radiosurgery (SRS) can occur. Often, surgical resection is
favored, as it frequently provides immediate symptom relief as well as pathological char-
acterization of any residual tumor. Should the pathological specimen contain viable tumor
cells, further radiation therapy is an option to sterilize the tumor bed. We evaluated the
use of repeat SRS (rSRS) in lieu of whole-brain radiation therapy (WBRT) as a means of
improving local control (LC) while minimizing potential toxicity and dose to the normal brain.
Materials/methods: A retrospective review was performed to identify patients with brain
metastases who underwent SRS and then surgical resection for locally recurrent or per-
sistent disease. From 2004 to 2014, 13 consecutive patients or 15 lesions were treated
with rSRS after resection, either post-operatively to the tumor bed (n=10, 66.6%) or after a
second local recurrence (n=5, 33.3%). LC, distant brain failure (DBF), and radiation toxicity
were determined using patient records, RECIST criteria v1.1, and CTCAE v4.03.
Results: At a median follow-up interval of 9.0 months (range 1.8–54.9 months) from time of
rSRS, five patients remain alive. Following rSRS, 13 of the 15 (86.6%) lesions were locally
controlled with an estimated 100% LC at 6 months and 75% LC at 1 year. However, 11 of
the 15 (73.3%) treated lesions developed DBF after rSRS with 3 of 13 patients proceeding
to WBRT. Two of 15 (13.3%) resulted in either grade 2 radionecrosis with grade 3 seizures
or grade 3 radionecrosis.
Conclusion: Repeat SRS represents a potential salvage therapy for patients with locally
recurrent brain metastases, providing additional tumor control with acceptable toxicity,
even in the setting of prior SRS and surgical resection. rSRS may be reasonable to use as
an alternative to WBRT in this setting.
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INTRODUCTION
Metastatic brain disease is a frequent cause of morbidity and
mortality in patients with cancer, occurring at rates as high as
40% (1–3). Without treatment, the prognosis is often poor, with
survival usually limited from weeks to months, frequently from
neurological death (4). The mainstays of treatment for brain
metastases include whole-brain radiotherapy (WBRT), stereotac-
tic radiosurgery (SRS), and surgical resection. WBRT has been
the primary treatment of brain metastases; however, it has been
associated with neurocognitive decline and decreased quality of
life (5, 6). Definitive SRS has benefits of excellent reported local
control (LC) rates, minimal invasiveness, and low risks of radia-
tion toxicity (7). Surgical resection may be indicated if the lesion
is large, progressive, and/or hemorrhagic causing a mass effect. If
resection is sought, it is usually combined with adjuvant radio-
therapy due to high local recurrence rates associated with surgery
alone (8).
As patients continue to live longer with metastatic brain disease,
local brain relapse and distant brain failure (DBF) may occur more
frequently, thus necessitating the treatment and management of
recurrent brain metastases. Salvage therapy options include repeat
SRS (rSRS), surgery, and WBRT. Unfortunately, there are no ran-
domized clinical trials for the retreatment of recurrent brain
metastatic disease. Nonetheless, there are a limited number of
studies and reports discussing salvage treatments; thus, their utility
and use may be extrapolated from the observational studies along
with clinical judgment. Therefore, the treatment plans are often
individualized, depending on many factors such as prior therapy,
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size, location, number of lesions, performance status, status of sys-
temic disease, symptoms, and graded prognostic assessment (9).
There have been concerns with tissue tolerance with re-irradiation
(10, 11). However, neurological complications from rSRS have
been reported to be minimal (12). Furthermore, acceptable dose
ranges of SRS were observed for previously irradiated brain tumors
with a range 15–24 Gy depending on tumor size (13).
In this unique case series, we present the clinical outcomes
of patients who had metastatic brain lesions initially treated
with definitive SRS, followed by surgical resection and rSRS for
recurrent brain disease.
MATERIALS AND METHODS
Following Institutional Review Board approval (PRO 13020306), a
retrospective review of all patients treated with SRS for metastatic
brain disease was completed. Patients were treated between Sep-
tember 2004 and May 2014 at the University of Pittsburgh Cancer
Institute, initially consisting of 1189 patients. Thirteen patients
(15 lesions) were identified who successfully completed the treat-
ment regimen sequence of SRS, surgical resection, and rSRS to
the same or adjacent location. Surgical resection was done fol-
lowing initial SRS due to either locally recurrent or persistent
disease. The definition of the adjacent location was based on a
close proximity to the previously irradiated site, such that the rSRS
treatment field would overlap with the previously treated field.
Pre-treatment data and patient characteristics collected included
diagnosis, tumor location, interval between treatments, treatment
volumes and doses for each session, baseline and subsequent
neurologic symptoms, and radiographic evidence of change in
tumor size. Initial SRS doses were delivered according to treatment
volume; however, for rSRS re-irradiation of previously resected
lesions, delivered dose was often fractionated to possibly reduce
radiation-related toxicities. Systemic therapies were not evalu-
ated in this patient population due to incomplete records for this
treatment modality.
Local failure (LF) and DBF were determined based on sympto-
matic and radiographic progression, utilizing the Response Evalu-
ation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (14).
Treatment-related toxicities such as radionecrosis and seizures
were scored using Common Terminology Criteria for Adverse
Events version 4.03 (CTCAE v4.03). An increase in any of the neu-
rological symptoms or new symptoms after re-irradiation without
disease progression was considered radiation treatment effect. Sur-
vival,LC,and DBF were estimated using the Kaplan–Meier method
from the time of either SRS or rSRS to the data of failure or last
follow-up/death. Statistical significance was defined with a critical
value of p< 0.05. Kaplan–Meier analysis and univariate Cox pro-
portional hazards regression with frailty model for correlated data
were used with Stata version 13 (15).
RESULTS
Baseline patient characteristics are outlined in Table 1. Briefly, the
study population consisted of 13 patients (15 treatments) with a
median age of 54 years who underwent rSRS to a tumor cavity after
initial SRS treatment and surgical resection. The most common
tumor histologies were melanoma (60%) and breast (13.3%) can-
cers. One patient had received prior WBRT before initial SRS. After
Table 1 | Baseline patient characteristics.
Patient characteristics n=13 patients
(n=15 lesions)
Age
Median (range) 53 years (30–70 years)
Gender 5 males, 8 females
KPS
Median (range) 80 (70–90)
Initial GPA score
Median (range) 2 (1–3)
Initial RPA score
Median (range) 2 (1–2)
Primary histology
Melanoma (%) 9 (60.0)
Breast (%) 2 (13.3)
Lung (%) 1 (6.7)
Renal (%) 1 (6.7)
Colon (%) 1 (6.7)
Endometrial (%) 1 (6.7)
Radiotherapy prior to repeat SRS
Median number of prior SRS treatments
excluding repeat SRS (range)
3 (1–6)
Whole-brain radiotherapy (%) 1 (6.7)
Number of active brain metastases at repeat
SRS
Median (range) 0 (0–4)
Extracranial disease controlled at repeat SRS
Yes (%) 8 (53.3)
No (%) 7 (46.7)
Treatment intent of rSRS to tumor bed
Adjuvant/prophylactic for local control (%) 10 (66.7%)
Control of recurrent disease (%) 5 (33.3%)
initial SRS, surgery was sought due to tumor progression and/or
hemorrhagic mass effect. The intent of treatment of rSRS to the
tumor bed was for adjuvant therapy with resection in 10 of the 15
lesions (66.7%), whereas the other 5 (33.3%) were for local pro-
gression post-resection. Also, eight (61.5%) of the patients treated
had no active extracranial disease at time of delivery of rSRS to the
resection cavity.
Table 2 displays the SRS and rSRS treatment characteristics
along with clinical outcomes. The median time period from SRS to
rSRS was 6.4 months (2.4–15.2 months). The overall median time
from rSRS to last follow-up was 9.0 months (2.2–54.9 months).
Five (38.5%) patients were alive at last follow-up. The 6- and
12-month estimates of overall survival from rSRS are 61.5%
(30.8.3–81.8%) and 43.1% (8.6–59.4%), respectively (Figure 1).
Patients with melanoma histology associated with an increased
risk of death (p= 0.049, 95% CI 1.01–99.3).
Crude LC of the tumor bed from rSRS was 86.7% with the
estimated Kaplan–Meier 6- and 12-month survivals at 100 and
75.0% (31.5–93.1%), respectively (Figure 2). The crude DBF rate
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Table 2 | SRS and rSRS characteristics and clinical outcomes.
SRS rSRS
Median dose (range) 21 Gy (18–27 Gy) 21 Gy (16–30 Gy)
Median volume (range) 4.3 cc (0.76–19.3 cc) 9.4 cc (0.57–23 cc)
Median number of
fractions (range)
1 (1–1) 3 (1–3)
Isodose 80% 80%
Treatment platform
Cyberknife 15 13
Trilogy – 1
TrueBeam – 1
Median time from SRS to resection (range) 3.8 months
(0.5–14.2 months)
Median time from resection to rSRS (range) 1.1 months
(0.7–4.4 months)
Median time from SRS to rSRS (range) 6.4 months
(2.4–15.2 months)
Overall survival from SRS
Median follow-up (range) 13.3 months (4.6–60.5)
6-month Kaplan–Meier estimate (95% CI) 93.3% (61.3–99.0%)
12-month Kaplan–Meier estimate (95% CI) 53.3% (26.3–74.4%)
Overall survival from rSRS
Median follow-up (range) 9.0 months (2.2–54.9)
Patients alive at last follow-up (%) 5 of 13 (34.5%)
6-month Kaplan–Meier estimate (95% CI) 61.5% (30.8.3–81.8%)
12-month Kaplan–Meier estimate (95% CI) 43.8% (8.6–59.4%)
Local control from rSRS
Crude (%) 13 of 15 (86.7%)
6-month Kaplan–Meier estimate (95% CI) 100.0%
12-month Kaplan–Meier estimate (95% CI) 75.0% (31.5–93.1%)
Distant brain control from rSRS
Crude (%) 4 of 15 (26.6%)
6-month Kaplan–Meier estimate (95% CI) 56.6% (27.3–77.9%)
12-month Kaplan–Meier estimate (95% CI) 40.4% (15.2–64.7)
from rSRS was 73.3% with estimated Kaplan–Meier distant brain
control rates of 56.6% (27.3–77.9%) and 40.4% (15.2–64.7) at 6-
and 12-months, respectively. Of note, there were two patients who
had neither LF nor DBF after rSRS, albeit with 2.2 and 2.8 months
follow-up given progression of extracranial disease resulting in
death.
Of the 11 patients with recurrent disease either as local or DBF
after salvage SRS, 1 succumbed to rapid neurological deteriora-
tion leading to death; 2 pursued supportive care alone; 5 were
treated with additional SRS, and the remaining 3 were given WBRT
(Table 3).
There were two patients who experienced radiation-related tox-
icity after rSRS. One developed radionecrosis at 1.5 months requir-
ing steroids (grade 2) and seizures from a temporal lesion requiring
multiple admissions and a complex multi-drug regimen for con-
trol (grade 3). The second patient demonstrated radionecrosis at
4.8 months post-rSRS requiring Avastin (grade 3).
FIGURE 1 | Overall survival from rSRS (hash marks represent censored
observation).
FIGURE 2 | Local control from rSRS (hash marks represent censored
observation).
DISCUSSION
Radiosurgery to the tumor bed following surgical resection with
prior SRS appears feasible as a salvage approach in patients who
have locally recurrent brain tumors. Using varying treatment plat-
forms, doses ranging from 16 to 30 Gy in one to three fractions and
a median planning treatment volume of 9.4 cc, the demonstrated
1-year local progression-free survival is 75% and overall median
survival of 11.2 months from rSRS with 13.3 months from ini-
tial SRS. At the present time, there are no known studies of this
treatment paradigm. However, there are two smaller known case
series that evaluated rSRS for LF previously treated with SRS. Jay-
achandran et al. and Minniti et al. reported median OS of 26 and
10.3 months, respectively (16, 17). Moreover, there are five known
cases series presenting the clinical outcomes of rSRS for recur-
rent distant brain metastatic disease after prior SRS, with only
three of the studies presenting overall survival from time of rSRS.
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Table 3 | Description of definitive treatments and outcomes.
Age at
SRS
Histology Time from
SRS to rSRS
(months)
Extracranially
active disease
at rSRS
rSRS
PTV
(cc)
rSRS
dose Gy
(fractions)
Time
rSRS to LF
(months)
Time
rSRS to DBF
(months)
Treatment
for recurrent
disease
Time to Last
follow-up from
rSRS (alive)
29 Melanoma 4.2 No 19.0 24 (3) – 2.3 SRS 5.7
51 Breast 15.2 No 6.3 20 (3) 7.1 – SRS 11.2 (alive)
52 Breast 7.4 Yes 9.4 18 (1) – – – 2.8
69 Melanoma 2.4 No 10.5 30 (3) – – – 2.2
59a Melanoma 7.3 Yes 6.6 21 (3) – 3.5 Palliation 3.7
59a Melanoma 4.5 Yes 2.4 16 (1) – 3.5 Palliation 3.8
40 Melanoma 2.5 No 0.6 21 (1) – 7.5 SRS 10.8 (alive)
62 Lung 9.0 No 5.4 24 (3) – 16.4 SRS/WBRT 51.6 (alive)
52 Renal cell 4.7 Yes 9.7 18 (1) – 17.5 SRS 54.9 (alive)
52 Melanoma 9.9 No 3.8 18 (1) 8.4 – Palliation 9
61 Melanoma 7.8 Yes 21.0 22 (3) – 1.1 SRS/WBRT 11.5
63 Endometrial 6.6 No 23.0 22 (3) – 8.3 WBRT 20
52 Colon 3.7 No 9.8 24 (3) – 20.6 SRS 43.5 (alive)
56b Melanoma 6.3 Yes 4.8 18 (1) – 0.7 – 1.8
56b Melanoma 5.8 Yes 9.6 22 (3) – 1.1 – 2.2
aSame patient.
bSame patient.
Chen et al., Kwon et al., and Mariya et al. presented median sur-
vivals from rSRS of 6.5, 7.3, and 11 months, respectively (18–20).
Though the median survival reported from all of the studies from
initial SRS was somewhat broader in range of 11.5–26 months (18–
22). In comparison, our clinical outcomes are comparable to these
prior published results for rSRS treatments, with the additional
treatment of surgical resection.
Repeat SRS has the ability to precisely target an intracranial
lesion or cavity with high dose irradiation while limiting exposure
to surrounding normal tissue. Nonetheless, re-irradiation partic-
ularly after radiosurgery has been cautiously approached due to
concerns for radionecrosis. The re-irradiation toxicity rates are
limited in the literature for previous rSRS studies. Kwon et al.
reported rates of symptomatic radionecrosis of 18.6% though did
not distinguish between rSRS for locally recurrent and DBF (18,
19). Bhatnagar et al., who investigated the use rSRS in primary and
metastatic brain lesions, reported an overall radionecrosis rate of
11.5% identified by MRI, although these patients were asympto-
matic (12). Recently, Jayachandran et al. reported radiation-related
toxicity rates of 14.8% (4 of 27 lesions) (16). In the present series,
severe toxicity rates were acceptable at a crude rate of 13.3%, with
84.6% of the patients able to complete the prescribed retreatment
course without interruption or complication. Resection between
SRS treatments may have in fact aided in limiting radiation toxicity,
since the previously irradiated tissue was removed, thus having a
lower amount of tissue being re-irradiated at a high dose. However,
the larger treatment volume of tumor bed SRS may have increased
the risk of radiation-related toxicities. Regarding this care series,
salvage SRS was often fractionated (one to three fractions) to
potentially reduce radiation-related toxicities in the setting of
re-irradiation. Perhaps, a higher fraction schedule (three to five
fractions) may be more appropriate to limit the risk of toxicity with
re-irradiation by reducing the biologically effective dose. There are
now a number of studies that have evaluated upfront treatment
of hypofractionated SRS for primarily large brain metastases and
have reported reasonable rates of adverse events with favorable LC
for both intact (23–25) and resected lesions (26).
In the context of alternative treatment options, these rates of
toxicity may be more acceptable than the potential neurocognitive
decline and reduced quality of life seen especially with long-term
survivors of WBRT (5, 6, 27). Additionally, current literature sug-
gests that systemic therapy has been largely ineffective in the
management of most brain metastases, primarily due to poor
blood–brain barrier penetrability, sub-therapeutic drug concen-
trations in the periphery of lesions (28), and chemo-resistivity (29,
30). In select groups and with newer biological agents, improved
blood–brain barrier penetration may lead to improvements in
intracranial disease control (31–34).
Of note, patients with histologically positive melanoma were
associated with increased mortality (p= 0.049), despite the small
sample size of this study. The median survival for melanoma was
3.8 months compared to the overall median of 11.2 months. This
effect on survival is likely due to the aggressive nature of melanoma
with a high propensity for DBF and extracranial progression (35).
As a result, judicious patient selection should be used in this
population with a limited life expectancy.
Given the relatively uncommon incidence of this treatment
course, this case series is limited by its small sample size and
patient selection bias, which should be taken into consideration
when reviewing feasibility and safety. However, the presented data
are unique and should re-assure oncologists that properly selected
patients may benefit from this salvage approach given limited
toxicity from re-irradiation. Similarly, repeat radiosurgery follow-
ing surgical resection can provide satisfactory rates of LC in lieu
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of WBRT. Further prospective studies should ultimately evaluate
the role of rSRS for patients with recurrent brain metastases in
appropriately selected patients.
CONCLUSION
Stereotactic radiosurgery after surgical resection and prior radio-
surgery appears to be feasible with a rare risk of late toxicity,
namely radionecrosis. This approach allows withholding of WBRT
to potentially avoid neurocognitive deficits earlier in the patient’s
course. However, these patients are at substantial risk for devel-
oping DBF and thus should be managed with close imaging
surveillance.
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